261 related articles for article (PubMed ID: 37103114)
1. Rosuvastatin Attenuates Progression of Atherosclerosis and Reduces Serum IL6 and CCL2 Levels in Apolipoprotein-E-deficient Mice.
Tsilimigras DI; Thanopoulou K; Salagianni M; Siasos G; Oikonomou E; Perrea DD; Nirakis N; Filis K; Tsioufis K; Tousoulis D; Sigala F
In Vivo; 2023; 37(3):994-1002. PubMed ID: 37103114
[TBL] [Abstract][Full Text] [Related]
2. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
[TBL] [Abstract][Full Text] [Related]
3. Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment?
Marzoll A; Melchior-Becker A; Cipollone F; Fischer JW
J Cell Mol Med; 2011 Feb; 15(2):232-43. PubMed ID: 20015203
[TBL] [Abstract][Full Text] [Related]
4. Lipingshu capsule improves atherosclerosis associated with lipid regulation and inflammation inhibition in apolipoprotein E-deficient mice.
Xu J; Ma C; Chen M; Rong S; Gao H; Xia Z; Huang F
Lipids Health Dis; 2018 Jul; 17(1):182. PubMed ID: 30064511
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.
Yu P; Xiong T; Tenedero CB; Lebeau P; Ni R; MacDonald ME; Gross PL; Austin RC; Trigatti BL
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):26-39. PubMed ID: 29162602
[TBL] [Abstract][Full Text] [Related]
6. Practical assessment of the quantification of atherosclerotic lesions in apoE⁻/⁻ mice.
Lin Y; Bai L; Chen Y; Zhu N; Bai Y; Li Q; Zhao S; Fan J; Liu E
Mol Med Rep; 2015 Oct; 12(4):5298-306. PubMed ID: 26239265
[TBL] [Abstract][Full Text] [Related]
7. [Effect and mechanism of recombinant hirudin on atherosclerotic plaques in apolipoprotein E knockout (ApoE(-/-)) mice].
Tian JF; Ge CJ; Lu SZ; Yuan F; Zhao K
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Feb; 35(2):198-203. PubMed ID: 25881466
[TBL] [Abstract][Full Text] [Related]
8. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
10. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
Guo X; Wang L; Xia X; Wang P; Li X
Biomed Pharmacother; 2019 Jan; 109():1445-1453. PubMed ID: 30551396
[TBL] [Abstract][Full Text] [Related]
11. Dengyinnaotong attenuates atherosclerotic lesions, gut dysbiosis and intestinal epithelial barrier impairment in the high fat diet-fed ApoE
Xiong M; Zhang Z; Cui J; Du X; Chen Y; Zhang T
J Ethnopharmacol; 2024 Jan; 318(Pt A):116916. PubMed ID: 37453620
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice.
Danzaki K; Matsui Y; Ikesue M; Ohta D; Ito K; Kanayama M; Kurotaki D; Morimoto J; Iwakura Y; Yagita H; Tsutsui H; Uede T
Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):273-80. PubMed ID: 22116098
[TBL] [Abstract][Full Text] [Related]
13. Ethanolic extract of propolis inhibits atherosclerosis in ApoE-knockout mice.
Fang Y; Sang H; Yuan N; Sun H; Yao S; Wang J; Qin S
Lipids Health Dis; 2013 Aug; 12():123. PubMed ID: 23941539
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis.
Grönros J; Wikström J; Brandt-Eliasson U; Forsberg GB; Behrendt M; Hansson GI; Gan LM
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2046-53. PubMed ID: 18790840
[TBL] [Abstract][Full Text] [Related]
15. YKL-40 promotes the progress of atherosclerosis independent of lipid metabolism in apolipoprotein E
Chen L; Zheng J; Xue Q; Zhao Y
Heart Vessels; 2019 Nov; 34(11):1874-1881. PubMed ID: 31114961
[TBL] [Abstract][Full Text] [Related]
16. SOAT1 deficiency attenuates atherosclerosis by regulating inflammation and cholesterol transportation via HO-1 pathway.
Wu N; Li RQ; Li L
Biochem Biophys Res Commun; 2018 Jun; 501(2):343-350. PubMed ID: 29567472
[TBL] [Abstract][Full Text] [Related]
17. α4β7 Integrin (LPAM-1) is upregulated at atherosclerotic lesions and is involved in atherosclerosis progression.
Zhi K; Li M; Zhang X; Gao Z; Bai J; Wu Y; Zhou S; Li M; Qu L
Cell Physiol Biochem; 2014; 33(6):1876-87. PubMed ID: 24970009
[TBL] [Abstract][Full Text] [Related]
18. TSLPR deficiency attenuates atherosclerotic lesion development associated with the inhibition of TH17 cells and the promotion of regulator T cells in ApoE-deficient mice.
Wu C; He S; Peng Y; Kushwaha KK; Lin J; Dong J; Wang B; Lin J; Shan S; Liu J; Huang K; Li D
J Mol Cell Cardiol; 2014 Nov; 76():33-45. PubMed ID: 25117469
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities.
Zhang X; Qin Y; Wan X; Liu H; Lv C; Ruan W; He L; Lu L; Guo X
J Transl Med; 2021 Feb; 19(1):62. PubMed ID: 33568202
[TBL] [Abstract][Full Text] [Related]
20. Xinmaikang (XMK) tablets alleviate atherosclerosis by regulating the SREBP2-mediated NLRP3/ASC/Caspase-1 signaling pathway.
Hou C; Jiang X; Sheng W; Zhang Y; Lin Q; Hong S; Zhao J; Wang T; Ye X
J Ethnopharmacol; 2024 Jan; 319(Pt 2):117240. PubMed ID: 37777030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
